We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Second MRSA antibiotic reaches the market.
- Authors
Fox, Jeffrey L
- Abstract
The article reports on the U.S. Food and Drug Administration's (FDA) approval of Orbactiv (oritavancin), a new drug to treat Grampositive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), in August 2014. The drug is developed by the Parsippany, New Jersey-based Medicines Co. Orbactiv is a semi-synthetic lipoglycopeptide antibiotic that the company inherited from the 2009 acquisition of Targanta Therapeutics Corp.
- Subjects
DRUG approval; UNITED States. Food &; Drug Administration; MEDICINES Co.; METHICILLIN-resistant staphylococcus aureus treatment; TARGANTA Therapeutics Corp.; ANTIBIOTICS
- Publication
Nature Biotechnology, 2014, Vol 32, Issue 10, p972
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1014-972